Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 30.00 | |
5 mg | In stock | $ 47.00 | |
10 mg | In stock | $ 67.00 | |
25 mg | In stock | $ 97.00 | |
50 mg | In stock | $ 147.00 | |
100 mg | In stock | $ 247.00 | |
200 mg | In stock | $ 368.00 | |
500 mg | In stock | $ 596.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 55.00 |
Description | ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2. |
Targets&IC50 | ALK:0.62 nM |
Cell Research | Three-day cell viability assays are carried out by plating 2,000, 1,500 and 2,000 cells per well of Ba/F3, PC9 or MGH121, respectively, into black transparent-bottom 96-well plates. On the same day for Ba/F3 cells and the following day for PC9 and MGH121 cells, the cells are treated with each TKI across a 10-dose range from 0.3 nM to 10 μM. After 72 h of drug treatment, cell viability is measured using the CellTiter-Glo assay. (Only for Reference) |
Synonyms | AP26113, Brigatinib, AP26113-analog |
Molecular Weight | 529.01 |
Formula | C26H34ClN6O2P |
CAS No. | 1197958-12-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 98 mg/mL (185.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 42 mg/mL (79.4 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ALK-IN-1 1197958-12-5 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR IGF-1R ALK Anaplastic lymphoma kinase (ALK) AP26113 AP 26113 Cluster of differentiation 246 inhibit CD246 Anaplastic lymphoma kinase Brigatinib AP-26113 AP26113-analog ALK IN 1 ALK tyrosine kinase receptor ALKIN1 Inhibitor inhibitor